An evaluation of CoWare Inc.'s Processor Designer tool suite for the design of embedded processors.
Access RightsWorldwide access
Franz, Jonathan D.
MetadataShow full item record
The goal of this thesis is to evaluate the Processor Designer family of tools from CoWare, Inc. Processor Designer uses the L.I.S.A. 2.0 (Language for Instruction Set Architecture) language. The evaluation is being performed to determine the suitability of the toolset for incorporation into a classroom environment and for the use in developing replacements for legacy processors. The main focus will be on the ease of use of the tools. This includes exploring how steep of a learning curve is involved with this new processor designer language and how well the tools have been documented. The limitations of the tools will also be explored, as far as what can and cannot be done in the language. The thesis is also intended to provide a tutorial introduction to the CoWare Inc. tool suite for future students.
Showing items related by title, author, creator and subject.
Design and synthesis of dihydronaphthalene vascular disrupting agents and indolequinone-based bioreductives. Dogra, Abhishek. (2007-03-08)Cancer remains a deadly affliction for millions across the United States, and the number of new cases is only expected to rise in the years to come. In the field of anticancer research, vascular disrupting agents (VDAs) ...
Modeling, design, and development of potential inhibitors of γ-glutamylamine cyclotransferase and inhibitors of cruzain as therapeutic agents for Chagas' disease. Chen, Shen-En, 1981- (2008-06-11)γ-Glutamylamine cyclotransferase (γ-GACT) catalyzes cyclization of the L-glutamyl moiety in the isolated ε-(L-γ-glutamyl)-L-lysine crosslink, thereby releasing lysine. Although implicated in the degradation of the crosslink, ...
Design, synthesis and biological evaluation of novel serotonin reuptake inhibitors and novel derivatives of a nitrogen-containing combretastatin analog. Miranda, Maria Graciela. (2006-10-13)Depression is a common and serious illness that affects one out of every ten Americans each year. Since the 1980's, selective serotonin reuptake inhibitors (SSRIs) have been the pharmaceuticals of choice for the treatment ...